Post-ASCO 2024 GU Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Professor Thomas Powles | Moderator: Professor Sumanta Pal & Dr Christos Kyriakopoulos
20 June | 10:00–12:00 CDT/ 16:00–18:00 BST/ 17:00–19:00 CEST

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.

Agenda

Timings are in CDT

10:00–10:25 | Session 1: Updates in penile and prostate cancer

• A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial – #5009: Fernando  Maluf
• Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153) – #LBA5000: Christos Kyriakopoulos
• CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer – #5001: Josep Maria Piulats
• Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with ¹⁷⁷Lu-PSMA-617 versus change of ARPI in PSMAfore – #5008: Michael Morris

10:25–10:45 | Panel discussion

10:45–11:05 | Session 2: Updates in bladder and kidney cancer

• Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results – #LBA4517: Antonio Cigliola
• Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial – #4509: Guru Sonpavde
• Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC) – #4505: Brian Rini

11:05–11:25 | Panel discussion

11:25–11:35 | Session 3: Updates in EGFR mutated lung cancer EGFR-targeted therapies

• Health-related quality of life and pain in a phase 3 study of [¹⁷⁷Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore) – #5003: Michael Morris
• EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL) – #5005: Stephen Freedland

11:35–11:55 | Panel discussion

11:55–12:00 | Closing remarks & end of webinar

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.